Lilly's Abemaciclib On Par With Ibrance In Breast Cancer, But Not 'Clearly Superior'

 
• By Lucie Ellis-Taitt
Two wild goats play-fight on the edge of a rock cliff with horns interlocked.
Lilly's abemaciclib will face off with Pfizer's Ibrance if approved in 2018

More from Clinical Trials

More from R&D